Thyrocare Technologies Ltd Share Price

PharmEasy Parent Narrows Q1 Loss as Revenue Grows 10% YoY

PharmEasy parent API Holdings has reported a significant improvement in its Q1FY27 performance, with its net loss narrowing to ₹29.6 crore from ₹145.4 crore in the same quarter last year. Revenue, meanwhile, increased 10% YoY to ₹1,754 crore. What stands out to me is that the improvement is not coming from revenue growth alone. The company has been tightening costs and focusing on debt reduction. EBITDA for the quarter stood at ₹39.3 crore, compared with an EBITDA loss of ₹12.8 crore a year ago. The balance sheet improvement is another important development. API Holdings said it had repaid ₹1,050 crore of outstanding debt after years of pressure on its finances following the acquisition of diagnostics chain Thyrocare. PharmEasy’s revenue grew 10% to ₹348 crore, while EBITDA loss narrowed sharply to ₹17 crore from ₹21 crore last year. The B2B business also reported 8% YoY revenue growth to ₹1,005.6 crore. In my view, narrowing losses along with positive EBITDA and debt reduction is a meaningful improvement. However, I would still focus on whether the company can sustain this progress over the next few quarters rather than judging the turnaround from one quarter alone.

See More

Stocks With Strong Future Guidance — Worth Tracking

• V-Marc • RR Kabel • Finolex • HFCL

• E2E Networks • MTAR Technologies • Syrma SGS • Netweb Technologies • Sterlite Technologies • Sansera Engineering • Azad Engineering • Omnitech Engineering • Dynamatic Technologies • Aequs • Rossell Techsys • Sona BLW • TD Power Systems • Ramkrishna Forgings • Happy Forgings • Shivalik Bimetal Controls • KSH International • Gland Pharma • Aarti Pharmalabs • Kwality Pharmaceuticals • Sudeep Pharma • Hitachi Energy India • Neogen Chemicals • Quality Power • Ather Energy • Sky Gold • Cupid • Sai Life Sciences • Electronics Mart India • Neuland Laboratories • Shilpa Medicare • Laurus Labs • Shadowfax Technologies • Sedemac Mechatronics • Siemens Energy India • Premier Energies • Navin Fluorine • Mold-Tek Technologies • Muthoot Microfinance • SJS Enterprises • Lloyds Engineering Works • Garware Hi-Tech Films • Universal Cables • Kalyan Jewellers • Bluestone Jewellery • P N Gadgil & Sons • TVS Motor • Bajaj Auto • Paytm • Eternal • IDFC First Bank • PNGS Reva Diamond Jewellery • Craftsman Automation • Apcotex Industries • Timex Group India • Deep Industries • Cholamandalam Investment & Finance • Equitas Small Finance Bank • Acutaas Chemicals • Apar Industries • CreditAccess Grameen • Lodha Developers • Shriram Finance • Sakar Healthcare • Rajratan Global Wire • Fineotex Chemical • Thyrocare Technologies • Ujjivan Small Finance Bank • Emmvee Photovoltaic Power • Gandhar Oil Refinery • NTPC Green Energy • Titan Company • Cyient DLM • Polycab India • Hindusthan Urban Infrastructure • Mahindra & Mahindra Financial Services • Huhtamaki India • Adani Energy Solutions • Dynamic Cables • Beta Drugs • Shyam Metalics & Energy • Anand Rathi Wealth • Prime Cable Industries • Groww • Landmark Cars • ICICI Bank • Bhansali Engineering Polymers • Poonawalla Fincorp • Jayaswal Neco Industries • Tatva Chintan Pharma Chem • Navkar Corporation • Federal Bank • Jio Financial Services • RBL Bank • L&T Finance • V2 Retail • SG Finserve

See More

Technical Analysis Thyrocare Technologies

The stock

is showing a strong bullish trend on the weekly chart. The stock has formed a clear higher-high and higher-low structure and has recently broken above its previous ₹520–550 resistance zone with strong momentum. It is currently trading around ₹624 close to the recent high indicating strong buying interest. Support & Resistance immediate support is around ₹580–560 while a stronger support zone lies near ₹520–500. On the upside, ₹640–650 is the immediate resistance zone. A sustained weekly close above ₹650 can open the way towards ₹680–700. Short-Term Outlook: The trend remains bullish but the recent sharp rally makes the stock slightly extended so chasing at current levels carries risk. Fresh buyers can look for a pullback towards ₹580–560 or a strong breakout above ₹650. Existing holders can continue to hold with a trailing stop-loss around ₹550. A weekly close below ₹520 would weaken the current bullish structure.

See More

Thyrocare Shares Fall 8% After Promoter Sells 10% Stake

shares fell nearly 8% after promoter Docon Technologies sold around 10% of the company's paid-up equity capital, triggering concerns over promoter stake reduction and near-term supply pressure. Key Details Shares Sold: 53.33 lakh shares Stake Sold: ~10% of paid-up capital Transaction Value: ₹667.69 crore Average Selling Price: ₹1,252.03 per share Promoter Holding: Reduced to 60.93% from 70.98% Docon: Continues to remain a promoter of Thyrocare. Why Did the Stock Fall? The immediate pressure is largely supply-driven. A promoter selling such a sizeable stake increases the available shares in the market and can weigh on investor sentiment, particularly when the transaction is executed at a substantial scale. However, the important point is that Docon has not exited the company. It continues to hold a majority stake of around 61%, so the transaction does not represent a change in control. There is also a broader financing context. Docon's shares in Thyrocare have been used as security for borrowings at the API Holdings level, with the company's filings showing the promoter stake remains pledged in connection with the refinancing arrangements.

See More

Thyrocare Technologies Ltd. fell nearly 7% after promoter Docon Technologies Pvt. Ltd. sold there shares

Shares of Thyrocare Technologies Ltd. fell nearly 7% on August 13 after promoter Docon Technologies Pvt. Ltd. sold a 9.9% stake in the diagnostics company through a block deal. According to Bloomberg data, Docon Technologies sold 15.77 million Thyrocare shares, reducing its holding to 51.02% from 60.92%. Thyrocare told CNBC-TV18 that no further stake sale is currently expected. The shares were reportedly offered at an indicative floor price of Rs 630–631 apiece, representing a discount of around 3% to Tuesday’s closing price. Despite the stake sale, the company maintained its 20% growth guidance and said it would reassess the outlook after the second quarter. Management also indicated that it would prioritise growth over margins.

See More